Evaluating the Effectiveness of Injectable Platelet-Rich Fibrin in Androgenetic Alopecia Management

Abstract

Objective: The present paper will assess the safety and effectiveness of injectable platelet-rich fibrin (iPRF) to treat androgenetic alopecia (AGA). AGA is one of the genetic disorders that lead to progressive loss of hair and adversely affect the quality of life. Existing therapies have shown limited efficacy, so the use of novel therapies is needed, and i-PRF is a growth factor-and cell proliferation promoter-rich biotherapeutic agent capable of stimulating hair growth and improving the scalp microenvironment.

Methods: One hundred patients with AGA that had received poor responses in conventional therapies were enrolled. i-PRF injections were administered and results were evaluated with hair scoring (hair density, vellus hair percentage and hair shaft diameter), physician assessment, scoring of, scalp inflammation (folliculitis, greasiness, dandruff, itching) and Dermatology Quality of Life Index (DLQI), rating of patient satisfaction and adverse reaction surveillance.

Results: There was high response rate to treatment with great improvement in hair density, hair thickness and percent vellus hair. There was a significant improvement in scalp inflammation scores, physician visual assessment,DLQI scores and patient satisfaction scores when compared to baseline. There were few side effects that were recorded and thus a positive safety profile.

Conclusion: Injectable PRF is a well-tolerated and effective approach to AGA that enhances the rise of hair and reducing scalp manifestations. These results indicate that i-PRF is a new promising treatment that can be offered to patients, who intend to achieve better treatment results in androgenetic alopecia.